 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...3435363738394041424344...7475» |
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Pre-treatment With Ranibizumab Aggravates PDT Injury and Alleviates Inflammatory Response in Choroid-Retinal Endothelial Cells. (Pubmed Central) - Aug 1, 2020
Pre-treatment with rani promotes PDT-caused apoptosis via triggering caspase 8-mediated extrinsic apoptosis, and caspase 8 might also play a pivotal role in the rani's function of suppressing PDT-induced necroptosis and NLRP3 inflammasome activation. Our results implicate that pre-treatment with rani may enhance the angio-occlusive efficiency of PDT and alleviate endothelial inflammatory response, which gives it a great advantage over post-treatment.
- || Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Clinical, Journal, Real-World Evidence: Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world study. (Pubmed Central) - Jul 31, 2020
We retrospectively reviewed the medical records of 126 eyes with nAMD treated with either intravitreal ranibizumab or aflibercept, including ophthalmologic examinations and spectral-domain OCT at baseline and months 3, 6, and 12 after first injection...In conclusions, IRCs and PED are associated with poor visual improvement in nAMD in a real-world setting. Both IRCs and SRF responded better than PED to anti-VEGF therapy.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study. (Pubmed Central) - Jul 31, 2020
Both IRCs and SRF responded better than PED to anti-VEGF therapy. The low incidence of AEs and AESIs demonstrated the good safety and tolerability of ranibizumab in unilaterally/bilaterally treated patients with nAMD in this real-world setting.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany. (Pubmed Central) - Jul 30, 2020
P=N/A
Low number of visits as well as high number of treatment decisions without the use of OCT may contribute to undertreatment and poorer functional outcomes in patients undergoing ranibizumab treatment for nAMD in Germany. One potential reason for this could be that OCT was not covered by insurance for all patients during the study.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment? (Pubmed Central) - Jul 29, 2020
There were no characteristics identified in which outcomes were superior with PRP compared with ranibizumab. These exploratory analyses provide additional support that ranibizumab may be a reasonable alternative to PRP for proliferative diabetic retinopathy over a 2-year period.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Anterior Segment Optical Coherence Tomography Angiography of Iris Neovascularization After Intravitreal Ranibizumab and Panretinal Photocoagulation. (Pubmed Central) - Jul 29, 2020
These exploratory analyses provide additional support that ranibizumab may be a reasonable alternative to PRP for proliferative diabetic retinopathy over a 2-year period. No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: A Phase ? Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects (clinicaltrials.gov) - Jul 26, 2020
P2, N=80, Recruiting, Sponsor: Tasly Pharmaceutical Group Co., Ltd
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: "Para-retinal" Vector Administration into the Deep Vitreous Enhances Retinal Transgene Expression. (Pubmed Central) - Jul 24, 2020
AAV vectors are large (about 4,000 kDa) compared with most intraocular drugs, such as ranibizumab (48 kDa), and the large size impedes diffusion to reach the retina from the usual injection site in the anterior/mid-vitreous...More efficient retinal delivery translates to using lower vector doses, with reduced risk of ocular inflammatory exposure. These results indicate that para-retinal delivery yields more effective vector concentration near the retina, thereby increasing the potential for better retinal transduction in human clinical application.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Efficiency analysis by mfERG and OCT of intravitreal injection with ranibizumab on diabetic macular edema. (Pubmed Central) - Jul 21, 2020
These results indicate that para-retinal delivery yields more effective vector concentration near the retina, thereby increasing the potential for better retinal transduction in human clinical application. OCT and mfERG fully demonstrate the importance of IVR for DME patients from the macular morphology and function, especially the significance of mfERG in this disease.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Management of Peripapillary Choroidal Neovascular Membrane in Patients With Idiopathic Intracranial Hypertension. (Pubmed Central) - Jul 19, 2020
Peripapillary CNVM, a rare complication of IIH, often resolves spontaneously with treatment of IIH. In vision-threatening and/or persistent cases, intravitreal anti-VEGF treatment may be a safe and effective therapeutic option.
- | Lucentis (ranibizumab) / Roche, Novartis
Reimbursement, Journal: Priority options of anti-vascular endothelial growth factor agents in wet age-related macular degeneration under the National Health Insurance Program. (Pubmed Central) - Jul 19, 2020
Under the restrictive insurance program in Taiwan, more patients and ophthalmologists chose to treat wet AMD using aflibercept. However, in clinical practice, no significant differences in efficacy or clinical outcomes were found between the patients treated with ranibizumab and those treated with aflibercept.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, Journal: Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography. (Pubmed Central) - Jul 16, 2020
IVR was effective in reducing both the SRD and non-SRD components of DME according to our optimized formula. The association between BCVA improvement and edema reduction was more significant in the SRD component.
- | Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids. (Pubmed Central) - Jul 16, 2020
These include reduction in HRS number, DRIL extension, CMT, cysts area at DCP. These data may help in further study of noninvasive imaging biomarkers for better evaluation of treatment response.
- | NN1213 / Novo Nordisk, Lucentis (ranibizumab) / Roche, Novartis, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Trial completion date: TAPAS: Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD (clinicaltrials.gov) - Jul 14, 2020
P2/3, N=55, Completed, Sponsor: King's College Hospital NHS Trust
These data may help in further study of noninvasive imaging biomarkers for better evaluation of treatment response. Active, not recruiting --> Completed | Trial completion date: May 2020 --> Dec 2019
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: VITCLEAR: A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy. (clinicaltrials.gov) - Jul 14, 2020
P=N/A, N=62, Active, not recruiting, Sponsor: King's College Hospital NHS Trust
Active, not recruiting --> Completed | Trial completion date: May 2020 --> Dec 2019 Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Nov 2020
- |||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema (clinicaltrials.gov) - Jul 8, 2020
P4, N=142, Not yet recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- ||||| Lytenava (bevacizumab-vikg) / Outlook Therap
Enrollment closed, Trial completion date, Trial primary completion date: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jul 8, 2020
P3, N=227, Active, not recruiting, Sponsor: Outlook Therapeutics, Inc.
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2020 --> Nov 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Jul 2021 | Trial primary completion date: Nov 2020 --> Jun 2021
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, P4 data, Pricing, Journal: Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use. (Pubmed Central) - Jul 7, 2020
This supports Australia's decision to pay the same price for each rather than giving a premium to aflibercept. Many other countries are likely overpaying for aflibercept if their utilization patterns are similar to Australia's, and could benefit from incorporating routine utilisation assessment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Glucose Metabolic Characterization of Human Aqueous Humor in Relation to Wet Age-Related Macular Degeneration. (Pubmed Central) - Jul 7, 2020
In total, 25 eyes of 25 patients with wAMD were divided into phakic (15 eyes), pseudophakic (10 eyes), and intravitreal injections of ranibizumab (13 eyes) wAMD groups...Compromised glucose TCA cycle and altered glutamine metabolism are implicated in the AH metabolism in wAMD. These findings highlight potential treatments for alleviating wAMD from a metabolic perspective.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Jul 3, 2020
Patients with poor initial VA tended to gain more vision, however, had poorer final VA. This underscores the importance of early detection and treatment of nv-AMD in maintaining superior outcomes.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Prospective, Single-Center, Six-Month Study of Intravitreal Ranibizumab for Macular Edema with Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-Perfused Retinal Area. (Pubmed Central) - Jul 3, 2020
Treatment with early intensive IVR therapy in NPDR patients with ME not only improved BCVA and CRT but also decreased MA turnover. However, in the study period of 6 months, IVR therapy did not show significant improvement in perifoveal non-perfused area.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials. (Pubmed Central) - Jul 3, 2020
P3
The strongest predictors of DR response to ranibizumab at month 6 were baseline DR severity and DME quiescence at month 3. Eyes with the most robust early improvements had moderately severe or severe NPDR or PDR at baseline.
- || Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Clinical, Journal: SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. (Pubmed Central) - Jul 2, 2020
No significant difference was found in the visual acuity improvement of the patients with PCV between the conbercept group and ranibizumab group at 6 months. However, conbercept was superior to ranibizumab monotherapy in the regression of polyps.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. (Pubmed Central) - Jul 2, 2020
Within the variable dosing regimen, MA incidence was higher when fewer injections were required. More injections, if required by disease activity, did not increase the risk for MA.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Ranibizumab in macular oedema secondary to branch retinal vein occlusion - 24 months of treatment. (Pubmed Central) - Jul 2, 2020
In this study, the effect of ranibizumab on functional and morphological parameters of the affected eye was monitored, the safety of this treatment was also evaluated. During the follow-up, a statistically significant improvement in VA was achieved in every visit in comparison to baseline parameters, the mean VA gain at the 3 month visit was 12,1 ETDRS letters (p.
- |||| Xlucane (ranibizumab biosimilar) / Stada, Xbrane, Helvetic
Trial completion date, Trial primary completion date: XPLORE: Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis (clinicaltrials.gov) - Jul 1, 2020
P3, N=580, Recruiting, Sponsor: Xbrane Biopharma AB
During the follow-up, a statistically significant improvement in VA was achieved in every visit in comparison to baseline parameters, the mean VA gain at the 3 month visit was 12,1 ETDRS letters (p. Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: May 2020 --> Nov 2020
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Ranibizumab and Aflibercept Levels in Breast Milk after Intravitreal Injection. (Pubmed Central) - Jun 28, 2020
Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: May 2020 --> Nov 2020 No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up. (Pubmed Central) - Jun 28, 2020
No abstract available No abstract available
- | Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study). (Pubmed Central) - Jun 28, 2020
No abstract available No significant differences in the rate of development or growth of MA over 24 months were observed between ranibizumab and aflibercept in nAMD patients treated using an identical T&E regimen.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS Study. (Pubmed Central) - Jun 27, 2020
P=N/A
The observed low injection frequency reflects a need for more rigorous treatment in real-world settings. NCT01318941.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration. (Pubmed Central) - Jun 27, 2020
Ranibizumab proved to cause a small increase in CCT, while CCT remained unchanged in the aflibercept group. Repeated intravitreal injections of 0.5 mg of ranibizumab or 2 mg of aflibercept can influence the morphology of the corneal endothelium but not CCT.
- | Lucentis (ranibizumab) / Roche, Novartis
'No presents anymore': Inside Novartis' scheme to boost Lucentis sales in Greece https://t.co/a9yuY0vO1O (Twitter) - Jun 26, 2020
- | Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy: Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) - Jun 25, 2020
P4, N=150, Not yet recruiting, Sponsor: Wake Forest University Health Sciences
Repeated intravitreal injections of 0.5 mg of ranibizumab or 2 mg of aflibercept can influence the morphology of the corneal endothelium but not CCT. Trial completion date: Mar 2021 --> Jun 2021 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Dec 2020 --> Mar 2021
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Anti-vascular endothelial growth factor for neovascular glaucoma. (Pubmed Central) - Jun 25, 2020
Currently available evidence is uncertain regarding the long-term effectiveness of anti-VEGF medications, such as intravitreal ranibizumab or bevacizumab or aflibercept, as an adjunct to conventional treatment in lowering IOP in NVG. More research is needed to investigate the long-term effect of these medications compared with, or in addition to, conventional surgical or medical treatment in lowering IOP in NVG.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Journal: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy. (Pubmed Central) - Jun 25, 2020
Multiple regression analysis revealed that time to recurrence extended by 15.5 months when the G allele of ARMS2 A69S increased by one allele (TT: 15.7±17.0, TG: 30.8±23.5, GG: 41.1±22.6 months). The combination therapy resulted in a favorable visual outcome for PCV during 5-year follow-up.
- | dexamethasone / Generic mfg., Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Biomarker, Journal: The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema. (Pubmed Central) - Jun 22, 2020
Ranibizumab and dexamethasone are effective in the treatment of DME, as demonstrated by functional improvement and morphological biomarker change. DME associated with SDN and HRS represents a specific inflammatory pattern for which dexamethasone appears to be more effective.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial. (Pubmed Central) - Jun 22, 2020
P=N/A
However, combination of macular grid photocoagulation showed no beneficial anatomical or functional effect during follow-up period, nor did it reduce the number of ranibizumab injections, either in ischemic group or non-ischemic group. We suggest that there is no need to combine macular grid photocoagulation in the treatment of ME secondary to BRVO in the future.
- | Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: CoRaLa II: Combination of Ranibizumab and Targeted Laser Photocoagulation (clinicaltrials.gov) - Jun 22, 2020
P3, N=110, Not yet recruiting, Sponsor: University of Leipzig
We suggest that there is no need to combine macular grid photocoagulation in the treatment of ME secondary to BRVO in the future. .
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Role of Cytokines in Ranibizumab Therapy for Macular Edema in Patients with Central Retinal Vein Occlusion. (Pubmed Central) - Jun 19, 2020
In patients with CRVO, the changes of visual acuity and ME after intravitreal ranibizumab were associated with inhibition of intraocular VEGF production. VEGF could be a useful marker for the response of ME to treatment.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Jun 19, 2020
P3
In this analysis of a major nAMD trial using CAM atrophy criteria, no differences were observed in incidence or progression rates of new MA among study arms, ranibizumab doses, or treatment regimens. Monthly versus PRN treatment did not influence MA incidence or progression.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry. (Pubmed Central) - Jun 19, 2020
Monthly versus PRN treatment did not influence MA incidence or progression. Neither ranibizumab nor aflibercept was superior to the other in terms of VA outcomes and treatment frequency at 3 years for nAMD.
- || Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong
Retrospective data, Review, Journal: A systematic review and meta-analysis to compare the efficacy of conbercept with ranibizumab in patients with macular edema secondary to retinal vein occlusion. (Pubmed Central) - Jun 19, 2020
In addition, conbercept has the statistically same visual gains and safety as ranibizumab in RVO-ME patients. Longer-term follow-up surveys on the safety and effectiveness of these 2 treatment regimens are required.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration. (Pubmed Central) - Jun 18, 2020
The study included 63 initially treatment-naive AMD patients who were analyzed for non-responsiveness and tachyphylaxis to intravitreal injections (IVI) of ranibizumab and aflibercept...Anti-VEGF therapy is an effective method of treatment for exudative AMD, however some patients may show week or no positive reaction or may develop tachyphylaxis. Awareness of these possible negative effects is an important clinical problem in the long-term management of AMD patients with VEGF inhibitors.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China. (Pubmed Central) - Jun 17, 2020
P1/2
Intravitreal injections of ranibizumab under "1 + PRN" regimen is a not only effective but also safe way to improve visual acuity of DME patients. And older age, lower baseline BCVA, VMT, and disruption of ellipsoid zone are predictors for final poor BCVA while PVD is a positive predictive factor for good final BCVA.
- || glimepiride / Generic mfg., Lusefi (luseogliflozin) / Taisho, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Combination therapy: Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial. (Pubmed Central) - Jun 17, 2020
Secondary and exploratory endpoints include safety and ophthalmologic and internal medical clinical parameters. This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000033961) and Japan Registry of Clinical Trials (jRCTs031180210).
- | Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial completion date, Trial primary completion date: OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) - Jun 16, 2020
P=N/A, N=80, Recruiting, Sponsor: Medical University of Vienna
This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000033961) and Japan Registry of Clinical Trials (jRCTs031180210). Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- || Lucentis (ranibizumab) / Roche, Novartis, abicipar pegol (AGN-150998) / Molecular Partners, AbbVie
Clinical, P2 data, Journal: Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Jun 15, 2020
Abicipar demonstrated durability of effect: BCVA and CRT improvements were similar between abicipar and ranibizumab at weeks 16 and 20 (8 and 12 weeks after the last abicipar injection and 4 weeks after the last ranibizumab injection). No serious AEs were reported.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity. (Pubmed Central) - Jun 15, 2020
No serious AEs were reported. One injection of 0.3 mg of intravitreal ranibizumab is effective in treating retinopathy of prematurity stage III mainly in zone I and II.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration. (Pubmed Central) - Jun 14, 2020
From the data of 48 treatment-naïve nAMD eyes that received intravitreal ranibizumab pro re nata for up to 12 months, we used the aqueous humour concentrations of C-X-C motif chemokine ligand 1 (CXCL1), CXCL12, CXCL13, interferon-γ-induced protein 10, monocyte chemoattractant protein 1 (MCP-1), C-C motif chemokine ligand 11, interleukin 6 (IL-6), IL-10, and matrix metalloproteinase 9 (MMP-9)...High MMP-9 at the first injection (β coefficient = 0.56, P = 0.01), CXCL12 at the third injection (β coefficient = 0.10, P = 0.0002), and IL-10 at the third injection (β coefficient = 1.3, P = 0.001) were predictor variables associated with the increased number of injections. In conclusion, aqueous humour protein concentrations may have predictive abilities of BCVA change over 12 months and the number of injections in pro re nata treatment of exudative nAMD.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Unrecognized ROPER in a child with a novel pathogenic variant in ZNF408 gene. (Pubmed Central) - Jun 13, 2020
FEVR in the presence of prematurity has been well described, falling under the proposed term ROPER. Genetic testing is key to confirm diagnosis.